Drug Profile
Drozitumab
Alternative Names: Anti-Death Receptor 5 monoclonal antibody - Genentech; Anti-DR5 mAb - Genentech; Anti-TRAIL Receptor-2 monoclonal antibody - Genentech; Apomab; PRO-95780; RG7425Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chondrosarcoma; Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer
Most Recent Events
- 05 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events, pharmacokinetics, and Cancer therapeutic trials sections
- 03 Jun 2007 Phase-II clinical trials in Non-Hodgkin's lymphoma in USA (IV)
- 03 Jun 2007 Phase-II clinical trials in Non-small cell lung cancer in USA (IV)